The GENetic Frontotemporal Dementia Initiative (GENFI): a new multi-centre platform for the study of frontotemporal lobar degeneration
Study Code / Acronym
GENFIAward Number
MR/J009482/1Programme
Research GrantStatus / Stage
CompletedDates
1 May 2012 -30 April 2014
Duration (calculated)
01 years 11 monthsFunder(s)
MRC (UKRI)Funding Amount
£211,668.58Funder/Grant study page
MRC UKRIContracted Centre
University College LondonContracted Centre Webpage
Principal Investigator
Professor Rossor, Martin NeilWHO Catergories
Development of BiomarkersImproving clinical trials
Understanding Underlying Disease
Disease Type
Frontotemporal Dementia (FTD)CPEC Review Info
| Reference ID | 274 |
|---|---|
| Researcher | Reside Team |
| Published | 12/06/2023 |
Data
| Study Code / Acronym | GENFI |
|---|---|
| Award Number | MR/J009482/1 |
| Status / Stage | Completed |
| Start Date | 20120501 |
| End Date | 20140430 |
| Duration (calculated) | 01 years 11 months |
| Funder/Grant study page | MRC UKRI |
| Contracted Centre | University College London |
| Contracted Centre Webpage | |
| Funding Amount | £211,668.58 |
Abstract
The frontotemporal lobar degenerations (FTLD) are a group of dementias characterized by progressive loss of brain cells from the frontal and temporal lobes. Frequently affecting a relatively younger age group compared with other dementias they collectively constitute a major socio-economic and human burden. FTLD commonly runs in families with many patients having a particular genetic mutation as the cause of their disease. The heritable nature of FTLD amplifies the human cost of these diseases but also creates a unique opportunity for making an earlier diagnosis and intervening at an early stage of disease. The understanding of FTLD has hugely advanced in recent years but this has yet to lead to any effective disease-modifying therapies. It is likely that any further progress towards this goal will depend on collaboration between specialist centres. The GENetic Frontotemporal Dementia Initiative (GENFI) aims to unite the expertise and resources of five internationally recognised research departments in the field. The objective of GENFI will be to set up a multi-national consortium with a common platform for the assessment of genetic FTLD patients. Clinical, behavioural, brain imaging, spinal fluid and blood sample data will be collected with the aim of developing markers of the onset and progression of disease in FTLD. Ultimately, the study will explore the feasibility of using the common framework developed here to support future large-scale studies of FTLD, in particular the development of clinical trials of disease-modifying interventions.
Aims
The objective of GENFI will be to set up a multi-national consortium with a common platform for the assessment of genetic FTLD patients. Clinical, behavioural, brain imaging, spinal fluid and blood sample data will be collected with the aim of developing markers of the onset and progression of disease in FTLD. Ultimately, the study will explore the feasibility of using the common framework developed here to support future large-scale studies of FTLD, in particular the development of clinical trials of disease-modifying interventions.